<DOC>
	<DOCNO>NCT02588287</DOCNO>
	<brief_summary>This study evaluate effect sofosbuvir/ledipasvir ( SOF/LDV ) treatment pharmacokinetics ( PK ) renal safety tenofovir . Subjects receive tenofovir-based antiretroviral therapy human immunodeficiency virus ( HIV ) protease inhibitor ( HIV PI/r ) initiate SOF/LDV treatment Hepatitis C virus ( HCV ) invite participate . The study consist three visit : screen visit two abbreviate 4-hour pharmacokinetic visit ( one initiate SOF/LDV second approximately 4 week initiate SOF/LDV ) .</brief_summary>
	<brief_title>Effects Sofosbuvir/Ledipasvir Treatment Pharmacokinetics Renal Safety Tenofovir</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Coinfection</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>On tenofovir ritonavirboosted PI least 30 day initiate HCV treatment SOF/LDV HCV RNA &lt; 48 copies/mL recent clinic visit eGFR &lt; 60 ml/min history renal disease Pregnant planning pregnancy Any medical , social , mentalhealth issue ( ) , opinion investigator , could interfere study participation study outcome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>